Andrew Cheng - Feb 1, 2022 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role: President & CEO, Director
Signature: /s/ Jonathan Young, Attorney-in-Fact
Stock symbol: AKRO
Transactions as of: Feb 1, 2022
Transactions value $: -$169,450
Form type: 4
Date filed: 2/3/2022, 06:12 PM
Previous filing: Mar 2, 2022
Next filing: Mar 2, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKRO	Common Stock	Options Exercise	$6.15K	+10K	+3.24%	$0.62^*	319K	Feb 1, 2022	Direct
transaction	AKRO	Common Stock	Sale	-$176K	-10K	-3.13%	$17.56	309K	Feb 1, 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AKRO	Stock Option (Right to Buy)	Options Exercise	$0	-10K	-3.12%	$0.00	311K	Feb 1, 2022	Common Stock	10K	$0.62	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 2, 2021, previously adopted by the reporting person.
F2	The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.98, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
F3	25% of this option vested on October 1, 2019, and the remaining 75% of this option shall vest and become exercisable in 36 equal monthly installments thereafter.